One Breakthrough
Menu
The world’s first sustainable solution to bacterial infection and disease.
Highly
Safe & Effective
Countless Applications
Future Safe
By 2050, the World Health Organizations predicts that 10 million people a year will be killed by antibiotic resistant superbugs. However, with our bacterio-matched phages, we can give governments, health providers, NGOs, and food growers the tools needed to ensure this doesn’t happen.
Our tailor-made bacteriophages are inexpensive, quick to produce, harmless to humans and animals, better for the environment and highly effective against exposed bacteria. Because of our unique, proprietary technology, we can produce targeted bacteria-killing phages in only weeks to months vs years as is the case with all other phage producers. Best of all, they complement and greatly reduce the need for antibiotics.
Joining the Fight
Against COVID-19
What if we could prevent the SARS-CoV-2 virus (that causes COVID-19) from infecting our bodies by removing it before it gets established?
This is the question driving Cytophage’s cutting-edge research in an entirely new focus for bacteriophage. The company is working on a phage nasal spray that goes directly to the area where SARS-CoV-2 infects the body – the mucosal membranes in the nose and throat. There, the phage promotes the production of antibodies through an adaptive immune response, giving protection from infection. This also results in antibodies that move throughout the body, allowing for general immunity in addition to site-specific protection.
Cytophage’s nasal-delivered vaccine will be comprised of bacteriophage genetically engineered to possess the SARS-CoV-2 spike gene/epitopes that will be produced and displayed on the surface of the phage. The spike gene/epitopes will be
genetically fused to a phage that infects Lactobacillus (the good bacteria added to yogurt and milk). This combination of phage and bacterial species treatment option will enable the phage to only replicate within the Lactobacillusbacterial species provided. With replication, the phage numbers increase to meet the demand needed to generate a robust response against a potential infection by SARS-CoV-2. This approach satisfies many idealistic vaccine product demands of low concentration of inoculum (as the phage will replicate within bacterial species provided and not disturb the resident microbiota in the mucosa and gut), stability at room and refrigerated temperatures, a non-invasive inoculation scheme, and lower manufacturing demands as high concentrations are not required.
Countless
Applications
Bacteriophage therapy has unlimited uses and is effective in eradicating bacterial disease and infection in three key areas.
Food Safety
In food safety, our phages help prevent disease and the spread of disease, without introducing antibiotics into the food chain or the environment.
Animal Health
Cytophage is developing bacteriophages that will reduce and ultimately replace the use of antibiotics for illness prevention and growth enhancement in livestock, starting with poultry.
Human Health
In human health, phages can address a full range of bacterial illnesses and conditions, from treating acne and eczema, alleviating internal bacterial infections such as pneumonia, preventing wound infections and battling outbreaks such as cholera or diphtheria.
Phages can also be used for the decontamination of hospital surfaces and counters, tools and instruments, beds and curtains, and anywhere else bacterial contamination is a concern.
Cytophage in the news
Student Opportunity
Let's get together at Phage Futures Europe!
Cytophage is sponsoring two students to present their research poster at Phage Futures Europe November 23-24 at Brussels.
News Release
Winnipeg Biotech Company Develops New Way to Catch and Kill COVID-19 Virus
Award-winning Cytophage Technologies Inc. today announced it is about to begin animal testing on a throat and nasal spray that will stop infection by the SARS-CoV-2 virus and its variants.
News Release
Winnipeg-made antibiotic alternative attracting international attention
Momentum is building this month at Winnipeg’s Cytophage Inc., as Dr. Steven Theriault, CEO, will be featured on the Interactive Investment forum — BioPub. It’s the fourth notable presentation of its kind this Fall for Theriault.
What is a
bacteriophage?
Bacteriophages are organisms that infect and kill bacterial cells. These natural killers of bacteria can overcome all of the cellular or organism-level defences.
What is a
bacteriophage?
Bacteriophages are organisms that infect and kill bacterial cells. These natural killers of bacteria can overcome all of the cellular or organism-level defences.
We can win the war against battlefield infection.
Cytophage was selected for the Defense Innovation Award 2019.
Winner of 2018 Nutreco Feed Tech Challenge
For our breakthrough innovation to help feed the world.
Swine Bacteriophage
We’re helping farmers meet the need and the demand for a healthier food chain.
Funded in part by the Canada and Manitoba governments through the Canadian Agricultural Partnership – Ag Action Manitoba Program. Learn more
Cytophage Technologies Inc. © 2019
Countless
Applications
Bacteriophage therapy has unlimited uses and is effective in eradicating bacterial disease and infection in three key areas.